KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Interest & Investment Income (2016 - 2018)

Emergent BioSolutions has reported Interest & Investment Income over the past 8 years, most recently at $701000.0 for Q3 2018.

  • For Q3 2018, Interest & Investment Income rose 10.05% year-over-year to $701000.0; the TTM value through Sep 2018 reached $1.4 million, down 26.2%, while the annual FY2017 figure was $1.8 million, 66.48% up from the prior year.
  • Interest & Investment Income for Q3 2018 was $701000.0 at Emergent BioSolutions, up from $306000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $701000.0 in Q3 2018 and troughed at $31000.0 in Q2 2014.
  • A 5-year average of $259263.2 and a median of $219000.0 in 2016 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 955.56% in 2014 and later plummeted 47.51% in 2018.
  • Year by year, Interest & Investment Income stood at $190000.0 in 2014, then crashed by 40.53% to $113000.0 in 2015, then soared by 155.75% to $289000.0 in 2016, then crashed by 44.64% to $160000.0 in 2017, then surged by 338.12% to $701000.0 in 2018.
  • Business Quant data shows Interest & Investment Income for EBS at $701000.0 in Q3 2018, $306000.0 in Q2 2018, and $222000.0 in Q1 2018.